TNF‐α inhibitors are the earliest biologics for psoriasis approved for marketing9; among them, adalimumab is a fully humanized anti‐TNF‐α monoclonal antibody that has demonstrated favorable efficacy for arthritic psoriasis and plaque psoriasis.10 The gene discussed is TNF; the disease is psoriasis vulgaris.